Background: The prevalence of both chronic kidney disease (CKD) and aortic stenosis (AS) increase with age. Although baseline CKD is frequent in patients undergoing transcatheter aortic valve replacement (TAVR), its significance among women is largely unknown. Methods: Women's INternational Transcatheter Aortic Valve Implantation (WIN-TAVI) is a multinational, prospective registry of women undergoing TAVR for severe AS. We included patients with available baseline estimated glomerular filtration rate (eGFR) and completed 1-year follow-up. Patients were categorized into three groups based on their eGFR: No CKD (normal kidney function to stage 2 CKD: eGFR ≥60 ml/min/1.73 m2); (b) mild CKD (stage 3a CKD: eGFR = 45–59 ml/min/1.73 m2); and (c) moderate/severe CKD (stage ≥3b CKD: eGFR <45 ml/min/1.73 m2). All events were adjudicated according to the Valve Academic Research Consortium (VARC)-2 criteria. Result: Out of 852 women undergoing TAVR, 326 (38.3%) had no CKD, 225 (26.4%) had mild CKD, and 301 (35.3%) had moderate/severe CKD. Women with higher stage of CKD at baseline were more likely to have a history of hypertension, diabetes, atrial fibrillation, anemia, chronic lung disease, hemodialysis, prior percutaneous coronary intervention, and pacemaker implantation. After multivariate adjustment, moderate/severe CKD was associated with a greater risk of 1-year VARC-2 safety endpoints [hazard ratio (HR) 1.68, 95% confidence interval (CI): 1.10–2.60], all-cause death (HR 2.00, 95% CI: 1.03–3.90), and composite of death, myocardial infarction, stroke or life-threatening bleeding (HR 1.70, 95% CI: 1.04–2.76). There were no differences in 30-day and 1-year VARC-2 efficacy and 30-day VARC-2 safety outcomes. Conclusion: CKD is associated with substantial and independent risk for mortality and morbidity at 1-year follow-up in women undergoing TAVR.

The impact of chronic kidney disease in women undergoing transcatheter aortic valve replacement. analysis from the women's INternational transcatheter aortic valve implantation (WIN-TAVI) registry / Bandyopadhyay, D.; Sartori, S.; Baber, U.; Cao, D.; Chandiramani, R.; Tchetche, D.; Petronio, A. S.; Mehilli, J.; Lefevre, T.; Presbitero, P.; Capranzaro, P.; Sardella, G.; Van Mieghem, N. M.; Chandrasekhar, J.; Dumonteil, N.; Fraccaro, C.; Trabattoni, D.; Mikhail, G. W.; Naber, C.; Kini, A.; Morice, M. -C.; Claessen, B. E.; Chieffo, A.; Mehran, R.. - In: CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. - ISSN 1522-1946. - 96:1(2020), pp. 198-207. [10.1002/ccd.28752]

The impact of chronic kidney disease in women undergoing transcatheter aortic valve replacement. analysis from the women's INternational transcatheter aortic valve implantation (WIN-TAVI) registry

Sardella G.;
2020

Abstract

Background: The prevalence of both chronic kidney disease (CKD) and aortic stenosis (AS) increase with age. Although baseline CKD is frequent in patients undergoing transcatheter aortic valve replacement (TAVR), its significance among women is largely unknown. Methods: Women's INternational Transcatheter Aortic Valve Implantation (WIN-TAVI) is a multinational, prospective registry of women undergoing TAVR for severe AS. We included patients with available baseline estimated glomerular filtration rate (eGFR) and completed 1-year follow-up. Patients were categorized into three groups based on their eGFR: No CKD (normal kidney function to stage 2 CKD: eGFR ≥60 ml/min/1.73 m2); (b) mild CKD (stage 3a CKD: eGFR = 45–59 ml/min/1.73 m2); and (c) moderate/severe CKD (stage ≥3b CKD: eGFR <45 ml/min/1.73 m2). All events were adjudicated according to the Valve Academic Research Consortium (VARC)-2 criteria. Result: Out of 852 women undergoing TAVR, 326 (38.3%) had no CKD, 225 (26.4%) had mild CKD, and 301 (35.3%) had moderate/severe CKD. Women with higher stage of CKD at baseline were more likely to have a history of hypertension, diabetes, atrial fibrillation, anemia, chronic lung disease, hemodialysis, prior percutaneous coronary intervention, and pacemaker implantation. After multivariate adjustment, moderate/severe CKD was associated with a greater risk of 1-year VARC-2 safety endpoints [hazard ratio (HR) 1.68, 95% confidence interval (CI): 1.10–2.60], all-cause death (HR 2.00, 95% CI: 1.03–3.90), and composite of death, myocardial infarction, stroke or life-threatening bleeding (HR 1.70, 95% CI: 1.04–2.76). There were no differences in 30-day and 1-year VARC-2 efficacy and 30-day VARC-2 safety outcomes. Conclusion: CKD is associated with substantial and independent risk for mortality and morbidity at 1-year follow-up in women undergoing TAVR.
2020
aortic stenosis; chronic kidney disease; transcatheter aortic valve replacement; WIN-TAVI registry; aged; aged, 80 and over; aortic valve; aortic valve stenosis; female; glomerular filtration rate; humans; kidney; registries; retrospective studies; risk assessment; risk factors; severity of illness index; sex factors; time factors; treatment outcome; renal insufficiency, chronic; transcatheter aortic valve replacement
01 Pubblicazione su rivista::01a Articolo in rivista
The impact of chronic kidney disease in women undergoing transcatheter aortic valve replacement. analysis from the women's INternational transcatheter aortic valve implantation (WIN-TAVI) registry / Bandyopadhyay, D.; Sartori, S.; Baber, U.; Cao, D.; Chandiramani, R.; Tchetche, D.; Petronio, A. S.; Mehilli, J.; Lefevre, T.; Presbitero, P.; Capranzaro, P.; Sardella, G.; Van Mieghem, N. M.; Chandrasekhar, J.; Dumonteil, N.; Fraccaro, C.; Trabattoni, D.; Mikhail, G. W.; Naber, C.; Kini, A.; Morice, M. -C.; Claessen, B. E.; Chieffo, A.; Mehran, R.. - In: CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. - ISSN 1522-1946. - 96:1(2020), pp. 198-207. [10.1002/ccd.28752]
File allegati a questo prodotto
File Dimensione Formato  
Bandyopadhyay_Impact-of-Chronic_2020.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.25 MB
Formato Adobe PDF
1.25 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1498561
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 12
social impact